Oriel Therapeutics awarded U.S. patent
RESEARCH TRIANGLE PARK, N.C. -- Oriel Therapeutics, an inhaled drug delivery company, was granted a U.S. Patent for multi-dose dry powder drug packages for holding inhalable dry powder substances. The patent covers aspects of Oriel's multi-dose dry powder inhaler technology that provides a package to apply vibration directly to a powder drug as well as a design for delivery of drugs. The package can be configured to deliver drugs in combination without blending. The vibration is individually tailored for a given drug product through use of powder physics principles and provides highly efficient dose delivery. This coupled with the powder delivery technology will allow for more rapid product development and improved patient administration and could impact the way in which some illnesses such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis can be treated.